MarketCap
Facebook
X
TelegramGeschäftsbericht 2022
hinzugefügt 21.12.2024
ADC Therapeutics SA Operativer Cashflow 2011-2026 | ADCT
Operativer Cashflow Jährlich ADC Therapeutics SA
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -233 M | -169 M | -122 M | -121 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -121 M | -233 M | -161 M |
Operativer Cashflow Vierteljährlich ADC Therapeutics SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -33.9 M | - | - | - | -55.1 M | - | - | - | -32.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -32.1 M | -55.1 M | -40.4 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Adagene
ADAG
|
-29.7 M | $ 2.83 | -2.75 % | $ 159 M |  China |
 |
Biogen
BIIB
|
2.88 B | $ 177.27 | 0.62 % | $ 25.8 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
64 M | $ 81.19 | -0.98 % | $ 1.57 B | USA |
 |
Amgen
AMGN
|
11.5 B | $ 339.82 | -0.91 % | $ 182 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
BioNTech SE
BNTX
|
890 M | $ 114.47 | -1.97 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.65 | -0.16 % | $ 1.52 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.56 | -0.78 % | $ 16.1 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.23 | -0.92 % | $ 7.77 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
CASI Pharmaceuticals
CASI
|
-26.8 M | $ 0.99 | - | $ 135 M | USA |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 10.0 | -1.43 % | $ 658 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Cerus Corporation
CERS
|
11.4 M | $ 2.3 | -1.08 % | $ 424 M | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.81 | -4.51 % | $ 116 M | France |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Beam Therapeutics
BEAM
|
-347 M | $ 28.26 | -3.52 % | $ 2.33 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 223.79 | -0.07 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 68.89 | -0.33 % | $ 9.21 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
240 M | $ 24.53 | -0.2 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
-37.7 M | $ 1.68 | 3.75 % | $ 80.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.03 | -1.71 % | $ 8.77 B |  Israel |
 |
Amneal Pharmaceuticals
AMRX
|
295 M | $ 13.77 | -2.45 % | $ 4.25 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |